Overview

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

Status:
Terminated

Trial end date:
2011-08-11

Target enrollment:

Participant gender:

Summary

This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis during concurrent paclitaxel and carboplatin chemotherapy with thoracic radiation in subjects with locally advanced non-small cell lung cancer (NSCLC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Joel Greenberger

Treatments:

Carboplatin
Manganese
Paclitaxel
Superoxide Dismutase